Martin H Voss

40PUBLICATIONS
190CO-AUTHORS
Molecular targetsTumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Aug 21, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

|Jul 29, 2026
Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma.

|Jan 31, 2025
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial.

Matthew Tucker, Yu-Wei Chen, Martin H Voss

|Jul 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.

Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack

|Oct 21, 2023
Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.

Ritesh R Kotecha, Andrea Knezevic, Kanika Arora

|Oct 03, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade.

Yasser Ged, Alejandro Sanchez, Sujata Patil

Pageof 7

Frequent Collaborators

22 joint publications

Robert J Motzer

16 joint publications

Ritesh R Kotecha

9 joint publications

Ed Reznik

7 joint publications

Maria Isabel Carlo